Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288820 | 1.00 | LMNA (0.47) | LMNATHRBOPRM1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL22117628 | 0.97 | LMNA (0.45) | LMNATHRBOPRM1 | |
| SCHEMBL9681077 | 0.78 | LMNA (0.39) | LMNATHRB | |
| SCHEMBL27803885 | 0.78 | THRB (0.44) | LMNATHRB | |
| SCHEMBL5891559 | 0.78 | THRB (0.44) | LMNATHRB | |
| SCHEMBL1568155 | 0.75 | THRB (0.57) | LMNATHRB | |
| SCHEMBL379036 | 0.75 | THRB (0.42) | LMNATHRB | |
| SCHEMBL6676705 | 0.75 | — | — | |
| SCHEMBL7166173 | 0.75 | TSHR (0.41) | LMNATHRBALDH1A1 | |
| SCHEMBL5662268 | 0.75 | TSHR (0.41) | LMNATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427451-B1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2018-10-25 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20160215007-A1 | METHOD OF PRODUCING PYRAZINO[2,1-C][1,2,4]TRIAZINE COMPOUND | PRISM PHARMA CO., LTD. (JP) | 2016-07-28 | — | — | US | disclosed |
| EP-3045464-A1 | METHOD OF PRODUCING PYRAZINO[2,1-C][1,2,4]TRIAZINE COMPOUND | PRISM Pharma Co., Ltd. (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-9193734-B2 | Alpha helix mimetics and methods relating thereto | PRISM PHARMA CO., LTD. (JP) | 2015-11-24 | — | — | US | disclosed |
| US-9126981-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2015-09-08 | — | — | US | disclosed |
| EP-2303887-B1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORP (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-9040531-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | PRISM BIOLAB CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2650295-A1 | Alpha helix mimetics and methods relating thereto | Prism Biolab Corporation (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267482-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM PHARMA CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8455488-B2 | Alpha helix mimetics and methods relating thereto | PRISM BIOLAB CORPORATION (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110092459-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | LMNA 255/4885THRB 1314/4885OPRM1 2293/4885 |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | LMNA 255/4885THRB 1314/4885OPRM1 2293/4885 |
| US-20130267482-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | COL1A1, PLOD3, THPO | LMNA 245/4885THRB 1425/4885OPRM1 2399/4885 |
| US-20160215007-A1 | METHOD OF PRODUCING PYRAZINO[2,1-C][1,2,4]TRIAZINE COMPOUND | TYMP, DTYMK, MTAP | LMNA 3744/4885THRB 852/4885OPRM1 170/4885 |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | LMNA 255/4885THRB 1314/4885OPRM1 2293/4885 |
| US-20110092459-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | COL1A1, PLOD3, THPO | LMNA 245/4885THRB 1425/4885OPRM1 2399/4885 |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | COL1A1, HDGF, HCCS | LMNA 251/4885THRB 759/4885OPRM1 2344/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | LMNA 255/4885THRB 1314/4885OPRM1 2293/4885 |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | LMNA 390/4885THRB 1298/4885OPRM1 3611/4885 |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | LMNA 390/4885THRB 1298/4885OPRM1 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.